Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma

NCT01238237 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT01238237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01238237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
Lead sponsor
Northwell Health
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2009
Completion date
January 31, 2016
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic astrocytoma (aoa), gbm, glioblastoma multiforme (gbm)